Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue

Breast Neoplasms Clinical Trial

Official title:

HR MAS MR Spectroscopy of Breast Cancer Tissue

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00184210
• Other study ID #: 154080/I30
• Status: Terminated
• Start date: January 2000
• Est. completion date: December 2020

Study information

• Verified date: March 2021
• Source: Norwegian University of Science and Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Breast cancer tissue is collected from women undergoing scheduled surgery for breast cancer. The tissue specimen are analyzed by MR spectroscopy. After MR, the intact tissue specimen can be analyzed by other methods, such as histopathology.

The MR spectral profiles are compared to clinical findings such as the patients diagnosis, lymph node status and tumor size.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1000
• Est. completion date: December 2020
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Palpable breast cancer lesion

Related Conditions & MeSH terms

• Breast Neoplasms

Locations

Country	Name	City	State
Norway	Norwegian University of Technology and Science	Trondheim

Sponsors (3)

Lead Sponsor	Collaborator
Norwegian University of Science and Technology	The Norwegian Women´s Public Health Association, The Research Council of Norway

Country where clinical trial is conducted

Norway, 

References & Publications (5)

Bathen TF, Jensen LR, Sitter B, Fjösne HE, Halgunset J, Axelson DE, Gribbestad IS, Lundgren S. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat. 2007 Aug;104(2):181-9. — View Citation

Giskeødegård GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjøsne HE, Dahl S, Gribbestad IS, Bathen TF. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res. 2010 Feb 5;9(2):972-9. doi: 10.1021/ — View Citation

Sitter B, Bathen TF, Singstad TE, Fjøsne HE, Lundgren S, Halgunset J, Gribbestad IS. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 2010 May;23(4):424-31. doi: 10.1002/nb — View Citation

Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006 Feb;19(1):30-40. — View Citation

Sitter B, Sonnewald U, Spraul M, Fjösne HE, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed. 2002 Aug;15(5):327-37. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MRimage of breast cancer tissue		0 hour